Danaher (NYSE:DHR) PT Raised to $250.00 at The Goldman Sachs Group

Danaher (NYSE:DHR) had its target price hoisted by equities researchers at The Goldman Sachs Group from $225.00 to $250.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the conglomerate’s stock. The Goldman Sachs Group’s price target suggests a potential downside of 7.44% from the company’s previous close.

A number of other analysts have also issued reports on DHR. Citigroup increased their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. TD Cowen lifted their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Barclays upped their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Bank of America boosted their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, Evercore ISI cut their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and an average price target of $276.88.

Danaher Trading Up 1.6 %

Danaher stock opened at $270.09 on Wednesday. Danaher has a 52 week low of $182.09 and a 52 week high of $276.31. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The firm has a market capitalization of $200.05 billion, a price-to-earnings ratio of 45.78, a P/E/G ratio of 4.11 and a beta of 0.83. The company has a 50 day moving average price of $254.99 and a 200 day moving average price of $248.82.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.90% and a net margin of 16.94%. Danaher’s revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.05 earnings per share. Research analysts forecast that Danaher will post 7.62 EPS for the current year.

Insider Buying and Selling

In other Danaher news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The disclosure for this sale can be found here. In the last 90 days, insiders sold 75,175 shares of company stock valued at $19,161,154. Insiders own 11.10% of the company’s stock.

Institutional Trading of Danaher

Hedge funds have recently modified their holdings of the company. Rational Advisors LLC acquired a new position in shares of Danaher in the second quarter valued at $219,000. Catalyst Financial Partners LLC raised its stake in shares of Danaher by 7.0% in the 2nd quarter. Catalyst Financial Partners LLC now owns 3,822 shares of the conglomerate’s stock valued at $955,000 after buying an additional 249 shares in the last quarter. Bristlecone Advisors LLC lifted its holdings in shares of Danaher by 7.8% during the 2nd quarter. Bristlecone Advisors LLC now owns 18,554 shares of the conglomerate’s stock worth $4,636,000 after acquiring an additional 1,341 shares during the period. EFG Asset Management North America Corp. acquired a new stake in shares of Danaher during the 2nd quarter valued at about $804,000. Finally, Townsend Asset Management Corp NC ADV increased its stake in Danaher by 8.3% in the second quarter. Townsend Asset Management Corp NC ADV now owns 21,035 shares of the conglomerate’s stock valued at $5,256,000 after acquiring an additional 1,611 shares during the period. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.